Previous 10 | Next 10 |
2023-05-18 18:38:14 ET Gainers: Farfetch Limited ( FTCH ) +18% . Ouster ( OUST ) +9%. Guardforce AI ( GFAI ) +4% . GSI Technology ( GSIT ) +4%. Losers: CaliberCos ( CWD ) -9%. Flowers Foods ( FLO ) -5%. DXC Te...
2023-05-17 02:56:26 ET Summary Key update: as we predicted, FDA approval for LUMRYZ, a unique once-at-bedtime narcolepsy treatment. Orphan Drug Exclusivity is granted until May 1, 2030, offering attractive patent protection. Launch expected in June 2023, with a fast sales ramp ant...
2023-05-05 15:44:00 ET Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) were up as much as 45.5% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence . The healthcare stock closed at $10.48 a share last week then climbed t...
2023-05-04 17:19:47 ET Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q1 GAAP EPS of -$0.48 misses by $0.10 . Cash, cash equivalents and marketable securities were $100.9 million as of March 31, 2023. The For further details see: Avadel Pharmaceutical...
-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy – -- FDA awarded LUMRYZ Orphan Drug Exclusivity through May 1, 2030 -- -- LUMR...
2023-05-03 14:00:06 ET Summary Avadel Pharmaceuticals has received full FDA approval for Lumryz, an extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The drug's once-nightly dosing regimen give...
- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy and safety data from pivotal Phase 3 REST-ON clinical trial - - Management to host con...
2023-04-19 08:20:09 ET Summary We maintain a Buy rating for Avadel Pharmaceuticals. We expect FDA approval of Lumryz in May and a potential launch in June. Recent financing initiatives provide AVDL with a robust cash runway and an established sales force to support Lumryz's la...
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Con...
2023-03-31 21:25:09 ET Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior ...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...